Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

NCT05535647 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG: Regorafenib and HAIC
DRUG: FOLFOX

Sponsor

Tianjin Medical University Cancer Institute and Hospital